Keith August
Overview
Explore the profile of Keith August including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marks L, Ritter V, Agrusa J, Agrusa J, Kamdar K, Rivers J, et al.
Blood Adv
. 2025 Jan;
9(6):1356-1365.
PMID: 39841960
Treatment options for patients with relapsed or refractory (R/R) anaplastic large cell lymphoma (ALCL) have increased in the era of targeted therapies such as brentuximab vedotin (BV) and anaplastic lymphoma...
2.
Hayashi R, Hermiston M, Wood B, Teachey D, Devidas M, Chen Z, et al.
Blood
. 2024 Mar;
143(20):2053-2058.
PMID: 38457359
Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or...
3.
Lee B, Yin D, August K, Noel-MacDonell J, Tracy M, Jensen D
Int J Pediatr Otorhinolaryngol
. 2022 Feb;
155:111065.
PMID: 35183919
Objectives: Invasive fungal rhinosinusitis (IFRS) is a potentially fatal disease that affects the severely immunocompromised and requires aggressive treatment. The objective of this study is to better describe predictors of...
4.
Perry J, Tao F, Roy A, Lin T, He X, Chen S, et al.
Nat Cell Biol
. 2020 Apr;
22(6):689-700.
PMID: 32313104
Leukaemia stem cells (LSCs) underlie cancer therapy resistance but targeting these cells remains difficult. The Wnt-β-catenin and PI3K-Akt pathways cooperate to promote tumorigenesis and resistance to therapy. In a mouse...
5.
Weerakoon-Ratnayake K, Vaidyanathan S, Larky N, Dathathreya K, Hu M, Jose J, et al.
Cells
. 2020 Feb;
9(2).
PMID: 32102446
The role of circulating plasma cells (CPCs) and circulating leukemic cells (CLCs) as biomarkers for several blood cancers, such as multiple myeloma and leukemia, respectively, have recently been reported. These...
6.
Shah N, Bhojwani D, August K, Baruchel A, Bertrand Y, Boklan J, et al.
Pediatr Blood Cancer
. 2020 Jan;
67(5):e28112.
PMID: 31944549
Background: In a multicenter phase 1 study of children with relapsed/refractory acute lymphoblastic leukemia (ALL), moxetumomab pasudotox, an anti-CD22 immunotoxin, demonstrated a manageable safety profile and preliminary evidence of clinical...
7.
Bhojwani D, Sposto R, Shah N, Rodriguez V, Yuan C, Stetler-Stevenson M, et al.
Leukemia
. 2019 Mar;
33(4):1061-1062.
PMID: 30842605
We thank the research coordinators and following physicians at pediatric cancer centers for contributing data to this project: Prashant Hiwarkar and Jayashree Motwani, Birmingham Women's and Children's Hospital, UK; Kelly...
8.
Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, et al.
Lancet Haematol
. 2018 Oct;
5(10):e450-e461.
PMID: 30290902
Background: Despite remarkable progress in the treatment of newly-diagnosed classical Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, treatment of relapsed or refractory disease remains challenging. The aims of this study...
9.
Bhojwani D, Sposto R, Shah N, Rodriguez V, Yuan C, Stetler-Stevenson M, et al.
Leukemia
. 2018 Sep;
33(4):884-892.
PMID: 30267011
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report...
10.
Li W, Cooley L, August K
Pathol Res Pract
. 2018 Mar;
214(6):919-923.
PMID: 29496305
Juvenile myelomonocytic leukemia (JMML) is a rare aggressive childhood leukemia characterized by an excess proliferation of cells of granulocytic and monocytic lineages. The WHO classifies JMML with the myelodysplastic/myeloproliferative neoplasms....